U.S. Banks Stock News

NYSE:AKR
NYSE:AKRRetail REITs

Is It Too Late To Consider Acadia Realty Trust (AKR) After Its Recent Share Price Rebound?

Investors may be wondering whether Acadia Realty Trust is offering good value at its current price, or if the easier gains have already passed. The stock recently closed at US$20.37, with returns of 4.9% over the last week, a 1.6% decline over the last month, a 1.3% decline year to date, 14.3% over the last year, 74.9% over three years, and 23.6% over five years. Recent coverage has focused on Acadia as a retail focused REIT, with ongoing attention on how its portfolio and tenant mix...
NYSE:CRGY
NYSE:CRGYOil and Gas

Is It Time To Reassess Crescent Energy (CRGY) After Its 78.8% One Year Surge?

If you are wondering whether Crescent Energy's current share price reflects its true worth, the recent trading pattern gives you plenty to think about. The stock has seen a 48.6% return year to date and 78.8% over the last year, with a recent 6.9% 30 day move and a 5.9% pullback over the past week that may have shifted how the market views its risk and reward trade off. Recent news coverage has focused on Crescent Energy's position in the US energy sector and how investors are reacting to...
NYSE:WES
NYSE:WESOil and Gas

Is Western Midstream Partners (WES) Still Attractive After Strong 5 Year Price Performance

If you are wondering whether Western Midstream Partners at around US$40.94 is still offering value, you are not alone. This article focuses on exactly that question. The unit price has moved by 2.1% over the last 30 days, with a 25.2% return over 1 year and a very large 217.2% return over 5 years. This naturally raises questions about how much value is already reflected in the current price. Recent news coverage has mainly centered on Western Midstream Partners as a key player in the US...
NYSE:ICE
NYSE:ICECapital Markets

Is It Too Late To Consider Intercontinental Exchange (ICE) After Recent Share Price Strength?

Wondering if Intercontinental Exchange at around US$161.97 is still a fair entry point or if the value story has already played out? This article focuses squarely on what the current price might imply. The stock has moved by 1.1% over the last 30 days and 5.6% over the past year, with a 56.5% return over 3 years and 44.1% over 5 years, which hints at a long track record that many investors will be weighing against today's valuation. Recent coverage has focused on Intercontinental Exchange as...
NYSE:PACS
NYSE:PACSHealthcare

Is It Too Late To Consider PACS Group (PACS) After Its 1-Year Surge?

Investors may be wondering whether PACS Group at around US$35.97 is still offering value after its strong run, or if the easy gains are already behind it. The stock has moved 11.9% over the last 7 days and 5.3% over the last 30 days, while the 1 year return of 286.8% contrasts with a year to date return of a 9.0% decline. Recent attention on PACS Group has centered on its strong 1 year share price performance and the healthcare services segment it operates in. This has made the stock more...
NasdaqGS:TTEK
NasdaqGS:TTEKCommercial Services

Is It Time To Reassess Tetra Tech (TTEK) After Recent Share Price Weakness

If you are wondering whether Tetra Tech's current share price offers good value or if you might be overpaying for quality, this article walks through the key valuation checks that matter most. The stock last closed at US$30.85, with a 0.7% decline over 7 days, an 8.1% decline over 30 days, and an 8.3% decline year to date. The 1 year, 3 year, and 5 year returns sit at 6.2%, 7.2%, and 16.9% respectively. Recent price movements are occurring against a backdrop of ongoing investor interest in...
NasdaqCM:PROP
NasdaqCM:PROPOil and Gas

Prairie Operating (PROP) Is Down 42.7% After Swinging to Profit and Issuing 2026 Guidance - What's Changed

Prairie Operating Co. reported past full-year 2025 results on March 30, 2026, showing revenue of US$241.65 million versus US$7.94 million a year earlier and moving from a net loss of US$40.91 million to net income of US$32.05 million, alongside detailed production disclosure. Management also issued production and earnings guidance for 2026, targeting average daily output of 25,500–27,500 Boe/d and net income of US$55 million to US$65 million, highlighting how operational scale now ties...
NYSE:SMG
NYSE:SMGChemicals

Scotts Miracle-Gro (SMG) Valuation Check As Recent Share Swings Stir Fresh Investor Attention

Why Scotts Miracle-Gro is drawing fresh attention Scotts Miracle-Gro (SMG) is back on investors’ radar after recent share price swings and updated performance metrics. This is prompting a closer look at how its lawn and garden business aligns with current portfolio goals. See our latest analysis for Scotts Miracle-Gro. Recent trading has been choppy, with a 1-day share price return of a 2.01% decline and a 7-day share price return of a 2.10% decline. However, the 1-year total shareholder...
NasdaqCM:ONCY
NasdaqCM:ONCYBiotechs

Is Oncolytics Biotech (ONCY) Price Reset Creating A Long Term Opportunity?

Wondering if Oncolytics Biotech at US$1.04 is priced for its potential or already running ahead of itself? This article walks through what the numbers are actually saying about value. The stock shows mixed return figures, with a 7 day return of 8.3%, 30 day return of 2.0%, year to date return of 5.7%, a 1 year return of 108.0%, a 3 year return of 11.9% decline, and a 5 year return of 64.5% decline that some investors may see as a reset in expectations. Recent attention around Oncolytics...
NasdaqGS:BBIO
NasdaqGS:BBIOBiotechs

BridgeBio Pharma Data Updates Shift Focus To Rare Disease Pipeline Potential

BridgeBio Pharma (NasdaqGS:BBIO) reported long term data for acoramidis (Attruby) in transthyretin amyloid cardiomyopathy, showing sustained efficacy, safety and quality of life outcomes over several years. The company highlighted the role of early and continuous treatment for ATTR-CM patients, citing ongoing unmet medical needs with existing options. BridgeBio submitted a New Drug Application to the US FDA for BBP-418, supported by Phase 3 data in limb-girdle muscular dystrophy type...
NasdaqGS:OMCL
NasdaqGS:OMCLMedical Equipment

Assessing Omnicell (OMCL) Valuation After Recent Share Price Volatility

Omnicell (OMCL) has been on investors’ radar after recent trading left the shares with a one-month return of about a 9% decline and a past three-month move of roughly a 30% decline. See our latest analysis for Omnicell. At a share price of US$35.47, Omnicell’s 7 day share price return of 3.9% contrasts with a 30 day share price return of about a 9% decline and a year to date share price return of about a 21% decline. The 1 year total shareholder return of 14.1% shows the effect of holding...
NYSE:VSH
NYSE:VSHElectronic

Is It Too Late To Consider Vishay Intertechnology (VSH) After Its 91% One-Year Surge?

If you are wondering whether Vishay Intertechnology at around US$21.33 is still offering value after a strong run, you are not alone. The stock has posted returns of 14.8% over the last week, 23.2% over the last month, 39.5% year to date and 91.2% over the past year. This naturally raises questions about what is already priced in and how much risk you are now taking. Recent coverage has focused on Vishay Intertechnology's position within the broader electronics space and how investors are...
NasdaqGS:XRAY
NasdaqGS:XRAYMedical Equipment

Is It Time To Reconsider DENTSPLY SIRONA (XRAY) After Years Of Share Price Weakness

Wondering if DENTSPLY SIRONA is trading at an attractive price right now? This article focuses squarely on what the current share price might imply about value. The stock last closed at US$11.86, with recent returns showing a 2.0% gain over 7 days, a 6.5% decline over 30 days, a 5.2% gain year to date, and a 2.7% decline over the past year, alongside deeper 3 year and 5 year declines of 68.6% and 79.6%. These moves sit against a backdrop where longer term shareholders have seen significant...
NYSE:SYK
NYSE:SYKMedical Equipment

The Tactical Trio: One AI Imaging Blueprint, One Orthopedic Value Play, One Surgical Compounder

Artificial intelligence in healthcare is attracting fresh attention as investors weigh higher for longer inflation risks, volatile bond yields, and energy driven cost pressures. While many sectors are wrestling with rising input and financing costs, AI in healthcare is focused on accuracy, efficiency, and better patient outcomes, themes that can matter across economic cycles. This article highlights 3 stocks from the Transformative AI Healthcare Stocks screener, a focused way to look at...
NasdaqGS:APLD
NasdaqGS:APLDIT

Applied Digital Q3 Loss Worsens To US$100.9 Million Challenging Margin Expansion Narrative

Applied Digital (APLD) just posted its Q3 2026 numbers, reporting revenue of US$126.6 million and a basic EPS loss of US$0.36. Trailing twelve month revenue came in at US$319.3 million, alongside a basic EPS loss of US$0.46. Over recent quarters, the company’s revenue has moved from US$38.0 million in Q4 2025 to US$64.2 million in Q1 2026, US$161.7 million in Q2 2026 and now US$126.6 million in Q3 2026. Over the same period, quarterly basic EPS shifted from a loss of US$0.12 to a loss of...
NYSE:CDRE
NYSE:CDREAerospace & Defense

Does Cadre’s New Universal Shelf Filing Reshape the Bull Case for Cadre Holdings (CDRE)?

In late March 2026, Cadre Holdings, Inc. filed a universal shelf registration to potentially issue common and preferred stock, debt securities, warrants, purchase contracts, and units. This broad capital-raising framework gives Cadre added financial flexibility that could support future initiatives but also raises questions about possible dilution and capital deployment priorities. Next, we’ll examine how this new capital-raising flexibility may influence Cadre Holdings’ earnings reset...
NYSE:RSI
NYSE:RSIHospitality

Rush Street Interactive Insider Sales Contrast With Strong Growth And Valuation

Rush Street Interactive (NYSE:RSI) reported recent insider stock sales by its Chief Legal Officer and Chief Financial Officer, carried out under prearranged 10b5-1 trading plans. The insider transactions come as the company continues to report strong fundamental performance, including better-than-expected quarterly results. RSI is also seeing considerable user growth in North American iCasino markets, which remains a key area of focus for the business. Rush Street Interactive operates...
NasdaqGS:QDEL
NasdaqGS:QDELMedical Equipment

QuidelOrtho (QDEL) Is Down 18.0% After Proposed NIH Funding Cuts Raised Diagnostics Demand Questions

A recent proposed 2027 US federal budget outlined sizeable spending cuts for health agencies, including a US$5.00 billion reduction for the National Institutes of Health, raising questions about future research funding across the healthcare ecosystem. For QuidelOrtho, the budget proposal has added another layer of uncertainty to an already pressured diagnostics landscape, where policy decisions can influence funding flows, customer priorities, and long-term demand for testing...
NasdaqCM:MVST
NasdaqCM:MVSTMachinery

Do Weak Technicals at Microvast (MVST) Undercut Confidence in Its Battery Innovation Ambitions?

Recent commentary on Microvast Holdings highlights weak technical indicators and broad selling pressure across investor groups, pointing to a cautious market stance toward the battery maker. This deterioration in technical momentum contrasts with earlier expectations tied to Microvast’s advanced battery innovations and global capacity expansion plans. We’ll now examine how this bearish technical and sentiment backdrop interacts with Microvast’s longer-term investment narrative built around...
NYSE:ED
NYSE:EDIntegrated Utilities

Can Analyst Optimism Around ED’s Q1 2026 Earnings Signal More Than Just Near‑Term Outperformance?

Consolidated Edison, Inc. has recently drawn attention as analysts grew more optimistic ahead of its 1st Quarter 2026 earnings release, scheduled for May 7, 2026, following a pattern of the company topping earnings estimates in recent quarters. This combination of a positive Earnings ESP and an upgraded Zacks Rank has reinforced the view that Consolidated Edison’s regulated utility operations may continue to surprise relative to consensus expectations. With this backdrop of analyst optimism...
NYSE:EVTC
NYSE:EVTCDiversified Financial

Does Nubity’s AWS Premier Status Recast EVERTEC’s (EVTC) Competitive Edge in Latin American Payments?

EVERTEC, Inc. recently announced that its cloud-focused subsidiary, Nubity by Evertec, has been recognized as an AWS Premier Tier Partner, the highest level within the Amazon Web Services Partner Network for providers with proven expertise in deploying AWS-based solutions. This designation highlights EVERTEC’s efforts to deepen its cloud capabilities, potentially strengthening its role in complex digital transformations across Latin America and the Caribbean. Next, we will explore how...
NYSE:MNR
NYSE:MNROil and Gas

Is Mach Natural Resources (MNR) Offering Value After Recent Share Price Weakness?

If you are wondering whether Mach Natural Resources is attractively priced or not, the starting point is understanding what the current share price is actually giving you. The stock recently closed at US$12.35, with a 12.2% decline over the last 7 days and a 5.2% decline over the last 30 days, while still showing a 9.8% return year to date and a 9.3% return over the last year. Recent trading has been shaped by ongoing interest in the oil and gas sector and how investors weigh commodity price...
OTCPK:JDVB
OTCPK:JDVBBanks

JD Bancshares (OTCPK:JDVB) Margin Decline Challenges Bullish Undervaluation Narrative

JD Bancshares (JDVB) just wrapped up FY 2025 with fourth quarter revenue of US$14.6 million and basic EPS of US$0.97, alongside trailing 12 month revenue of US$56.9 million and EPS of US$3.78, compared with FY 2024 trailing 12 month revenue of US$55.6 million and EPS of US$3.97. Over that same trailing 12 month window, net income moved from US$13.6 million in FY 2024 to US$13.0 million in FY 2025. This may prompt investors to focus on how margins and overall profitability quality shape the...
NYSE:STZ
NYSE:STZBeverage

Constellation Brands (STZ) Return To Profitability Tests Bullish Margin Narrative After FY 2026 Results

Constellation Brands (STZ) has just wrapped up FY 2026 with fourth quarter revenue of US$1,920.2 million and basic EPS of US$1.16. The latest trailing twelve month figures show revenue of US$9.1 billion and EPS of US$9.62. Over recent periods, quarterly revenue has ranged from US$1,920.2 million to US$2,515 million, with basic EPS between US$1.16 and US$3.40. This sets up a picture of earnings that now sit against a return to profitability on a trailing basis and margins that investors will...